Ovagen

Quickstart Highlights

Ovagen is a synthetic ultrashort tripeptide (Glu-Asp-Leu; EDL) studied as a bioregulator of gastrointestinal and liver tissues. In vitro studies demonstrate that EDL increases cell proliferation and modulates aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures. No controlled human trials exist; available data are preclinical and cell-based. This educational protocol presents a once-daily subcutaneous 20-day course (repeated two to three times per year).

• Reconstitute: Add 2.0 mL bacteriostatic water → 10 mg/mL (10,000 mcg/mL) concentration.
• Typical daily range: 500–1000 mcg once daily for a 20-day course (500 mcg for Days 1–5, then 1 mg); repeat 2–3 times per year.
• Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U-100 insulin syringe; 500 mcg = 5 units, 1 mg = 10 units.
• Evidence: Sparse. Published guides for Ovagen disagree on dose by an order of magnitude; this course takes the middle of that range. Treat as low confidence.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the 20-day course regimen.

• Goal: Support gastrointestinal and hepatic tissue bioregulation over time.
• Schedule: One daily subcutaneous injection for a 20-day course (10 days minimum); repeat two to three times per year with at least 3 months between courses.
• Dose Range: 500–1000 mcg daily; 500 mcg for Days 1–5, then 1 mg.
• Reconstitution: 2.0 mL per 20 mg vial (10 mg/mL) for clean 5- and 10-unit readings.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested 20-day course (Khavinson-style bioregulator schedule).

• Start: 500 mcg daily for Days 1–5 to assess tolerance.
• Target: 1000 mcg (1 mg) daily from Day 6 through Day 20.
• Frequency: Once per day (subcutaneous).
• Course Length: 20 days standard (10 days minimum); 2–3 courses per year with at least 3 months between courses. Do not extend continuously.
• Timing: Any consistent time; rotate injection sites daily.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; for long-term stability, −80 °C (−112 °F) is optimal.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within a few days or aliquot and freeze to minimize hydrolysis.
• Do not store thawed solution longer than 1–2 days at 2–8 °C; avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (30-unit or 50-unit preferred for low-volume accuracy); dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Label the vial with date/time of reconstitution, diluent volume, final concentration, and initials.

How This Works

Ovagen (EDL) is an ultrashort peptide believed to enter cells and bind DNA, thereby modulating gene expression and protein synthesis. In vitro studies show EDL increases cell proliferation and alters aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures, suggesting cytoprotective effects. Such ultrashort peptides are known to influence cell differentiation, proliferation, and apoptosis via gene regulation. Additionally, EDL has been identified as an HIV-1 protease inhibitor with binding affinity in the enzyme active site.

Potential Benefits & Side Effects

Observations from preclinical and in vitro literature (no controlled human trials available).

• May support gastrointestinal and hepatic tissue bioregulation based on ultrashort peptide bioregulator research.
• In vitro studies indicate potential cytoprotective effects via modulation of aging-related gene expression.
• Ultrashort peptides generally exhibit rapid metabolism and low immunogenicity.
• Side effects are not well characterized due to lack of human clinical data; mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced diet supporting gastrointestinal and liver health.
• Maintain regular physical activity to support overall metabolic function.
• Prioritize sleep and stress management to support adherence and recovery.
• Avoid excessive alcohol and hepatotoxic substances during the protocol.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

• Clean the vial stopper and skin with 60–70% alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid tissue irritation; keep at least ~2 cm between injections on the same area.
• Use a 23–25 gauge needle (5/8″ length) or standard insulin syringe needles (28–31G).

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs